Size of Indian Pharma Market

January 3rd, 2012|

Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).

Modi asks pharma cos to focus on real research

December 15th, 2009|

“In this age of product-process patent and intellectual property rights, discovery of new drugs holds significance. Moreover, a social environment, under which the firms follow the rule at their own, should also be created. If this is not done, it will make way for the rise of holistic healthcare culture in India too,” said Gujarat’s Chief Minister Narendra Modi.

Sandoz launches first generic version of Prograf capsules

August 10th, 2009|

Sandoz today announced the introduction of tacrolimus capsules, a generic equivalent of Prograf®, in the US. Tacrolimus is an immunosuppressive treatment used to help prevent rejection of a kidney or liver transplant.

Pharmaceutical Industry at Crossroads

July 7th, 2009|

To beat the financial crisis, experts say that many big pharmaceutical firms are seeking to collaborate or merge their businesses to better develop and market new blockbuster drugs.

Gujarat-based pharma firms in pink of health

May 26th, 2009|

In the time of economic slowdown when major companies are facing pressure on their balance sheets, Gujarat-based pharmaceutical firm have registered a healthy growth and seen substantial rise in net profit in the financial year 2008-09.

Cardiome bags US 60 mn dollar from Merck as collaboration, license pact become effective

May 21st, 2009|

Cardiome Pharma Corp announced that the waiting period under the Hart-Scott-Rodino Act for the collaboration and license agreement with Merck & Co. Inc and a Merck affiliate for development and commercialisation of vernakalant, an investigational candidate for the treatment of atrial fibrillation, has expired and the agreement is now effective.

Dr Reddys to tap rural, north Indian markets for growth Plans to increase products in therapeutic

May 20th, 2009|

Pharma major Dr Reddy’s Laboratories Ltd has readied an action plan to increase its revenue growth in the domestic market, which had dipped below the industry average last fiscal.

The outsourcing boom grows for non-core pharma activities

May 17th, 2009|

There's nothing like a darkening economic climate and rising competitive pressures to focus a business's priorities.

Pharma cos may have to start collaborating

May 12th, 2009|

Firms are under pressure due to the shrinking pipeline of new drugs, slowing growth and increased competition.

Present Scenario of The Biotech Industry

April 16th, 2009|

Last year, the Biotech industry as a whole achieved much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40%. While NASDAQ Biotech Index declined only 12.6%, and AMEX Biotech Index was down 17.7%.

Seattle Genetics, Millennium ink collaboration pact to develop ADCs

April 7th, 2009|

Seattle Genetics, Inc has entered into a worldwide collaboration agreement with Millennium: The Takeda Oncology Company, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, for the development of antibody-drug conjugates (ADCs).

Foreign loans did not work for Wockhardt

April 4th, 2009|

Pharma major, Wockhardt, has been in the news for a while. This was after a flurry of events. Its chairman Habil Khorakiwala resigned elevating his son, Murtuza Khorakiwala to the post of Managing Director.

Pharma MNCs Raise India Stakes for Bigger Role

April 2nd, 2009|

It is purely coincidental that recently Novartis and Mylan announced plans to significantly hike equity stakes in their Indian subsidiaries. Swiss firm Novartis presently holds a little less than 51 percent stake in its Indian arm, while Pittsburgh-headquartered Mylan has 71 percent in Matrix Labs, the Hyderabad-based company it acquired in 2006 for a total consideration of $736 million.

Covance Buys Swiss Pharma Contract

March 15th, 2009|

Covance Inc. (NYSE: CVD) has acquired Swiss Pharma Contract, a 50-bed clinical research company based in Basel, Switzerland. No financial terms were disclosed. According to VentureWire, Swiss Pharma raised seed funding in 1998 from Novartis Venture Fund.

Gilead $1.4 Bln CV Therapeutics Deal Tops Astellas

March 11th, 2009|

Gilead Sciences Inc. agreed to buy CV Therapeutics Inc. for about $1.4 billion to gain chest-pain and heart drugs, topping a hostile offer from Japan’s Astellas Pharma Inc.

Sun Pharma loses $ 3 billion potential from US

February 19th, 2009|

Sun Pharmaceutical Industries, one of India's largest drugmakers by market value, has lost out on a $ 3 billion revenue potential from the US market. This was after a rival beat it to gain the US regulator's approval to sell the world's best selling anti-depressant.

CLC bio launches next generation sequencing data analysis

February 10th, 2009|

CLC bio just launched their new enterprise level product line, consisting of CLC Science Server and CLC Genomics Server.

Ethex recalls prescription prenatal & iron supplements products

February 8th, 2009|

Ethex Corporation, a subsidiary of KV Pharmaceutical Company, is issuing a voluntary nationwide recall of prescription prenatal and iron supplements products (all lots within their expiration dates) at a wholesale level.

Merck’s phase 3 trial of safinamide as adjunctive therapy to levodopa meets endpoint

February 6th, 2009|

Merck KGaA and its Merck Serono division together with partner Newron Pharmaceuticals SpA announced that the first phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours. "ON" time represents periods when Parkinson's patients experience their best level of motor functioning.

deCODE discovers first common genetic variants affecting the risk of many types of cancer

January 19th, 2009|

Scientists at deCODE genetics and colleagues from the US and ten European countries announced a long-awaited first in cancer research: the discovery of common single-letter variations in the human genome (SNPs) linked to susceptibility not of one, but several different types of cancer, including those of lung, bladder, prostate, skin and cervix.